NOT FOR RELEASE OR DISTRIBUTION IN THE USA, CANADA, AUSTRALIA OR JAPAN.

SHOP APOTHEKE EUROPE shareholders' meeting: Company accelerates European growth.

- All proposals made by management approved by large majority.

- Strategic orientation confirms profitable growth course.

- CEO Michael Köhler, CEO: "SHOP APOTHEKE EUROPE is the growth story in the European online pharmacy market."

Venlo, the Netherlands, 16 May 2017 - The annual shareholders' meeting of SHOP APOTHEKE EUROPE N.V., Europe's leading online OTC pharmacy (OTC = over the counter = non-prescription medications) today approved all proposals put forth by management by a large majority.

The members of the Board of Management explained the reasons for the dynamic growth of the company's business over the 2016 fiscal year. "Online sales of non-prescription medications and pharmacy-related beauty and personal care products have increased substantially in the past year and the market continues to offer enormous potential for growth. In many of our European markets, the online penetration rate is still low in this segment, and will rise significantly over the next couple of years. Furthermore, our product portfolio addresses a broad target audience whose needs will continue to grow as they get older," says Michael Köhler, CEO of SHOP APOTHEKE EUROPE.

Dr. Ulrich Wandel, CFO of SHOP APOTHEKE EUROPE, adds: "In fiscal year 2016, we have successfully entered several promising European markets and further improved our strong market position with the ahead-of-schedule integration of FARMALINE. In addition, we were able to lower administrative costs compared to revenues. We are a debt-free company and with the funds raised from our initial public offering in October 2016, we are in pole position for accelerated growth."

In consideration of the company's dynamic first quarter growth, the Board of Management has confirmed it's guidance of a 45 % - 55 % increase in revenues for the 2017 fiscal year.
The acceleration of growth compared to the previous year is primarily driven by the company's international business. The consolidated gross margin is expected to increase
in line with the projected growth. Management also expects an improvement of the consolidated EBITDA margin to around -2 % to -3 %.

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is Continental Europe's leading online OTC pharmacy with a portfolio that focuses on OTC medication and pharmacy-related beauty and care products (BPC). The Company operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, the TÜV-certified shop-apotheke.com is market leader. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to 2.1 million active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.

SHOP APOTHEKE EUROPE generated EUR 177 million in revenues in the financial year of
2016. Headquartered in Venlo (the Netherlands), SHOP APOTHEKE EUROPE also has offices
in Cologne, Düsseldorf, Paris and Tongeren, Belgium. The online pharmacy has been listed
on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since
13 October 2016.

MEDIA CONTACTS.

Trade and public media:
Sven Schirmer
Mobile: +49 152 28 50 63 61
E-Mail: presse@shop-apotheke.com

Financial media:
Thomas Schnorrenberg
Mobile: +49 151 46 53 13 17
E-Mail: presse@shop-apotheke.com

Investor Relations:
Dr. Ulrich Wandel
Phone: +31 77 850 6117
E-Mail: ulrich.wandel@shop-apotheke.com

DISCLAIMER.

This announcement contains forward-looking statements that relate to the future course of business and future financial performance, as well as future transactions or developments concerning SHOP APOTHEKE EUROPE. The bases of these statements are current expectations and assumptions of SHOP APOTHEKE EUROPE's management, of which a large number are outside SHOPE APOTHEKE EUROPE's sphere of influence. These statements are therefore subject to a variety of risks and uncertainties. If such risks and uncertainties occur, or if the underlying expectations do not materialize or the assumptions made are not correct, the actual events, both positive and negative, may differ materially from those events contained in the forward-looking statements. SHOP APOTHEKE EUROPE assumes no obligation to update these forward-looking statements or to correct them in the event of occurrences or developments other than those anticipated. Such updates or corrections are not intended.